Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Crispr Therapeutics AG (CRSP) vs Cognizant Technology Solutions Corp (CTSH) Price & Performance

Crispr Therapeutics AGTrade
Cognizant Technology Solutions CorpTrade

Price performance (Past 24H)

Key statistics

Crispr Therapeutics AG vs Cognizant Technology Solutions Corp — how do they compare? Crispr Therapeutics AG trades at $53.87 (market cap $5.23B), while Cognizant Technology Solutions Corp trades at $57.4 (market cap $26.40B). The key difference: Cognizant Technology Solutions Corp is far larger — about 5× Crispr Therapeutics AG's market cap, and Cognizant Technology Solutions Corp pays a 2.25% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.

CRSPCTSH
Market Cap
$5.23B$26.40B
Sector
HealthTechnology
52-Week High
$76.78$86.70
52-Week Low
$44.34$38.73
Enterprise Value
$3.65B$27.44B
Dividend Yield
2.25%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Crispr Therapeutics AG

CRISPR Therapeutics (CRSP) trades at $53.51, down slightly by 0.02% today. The stock shows bullish technical signals with strong support at $53 and resistance at $54. Fundamentally, the company reports widening losses with a net income margin of -4,101.26% in 2025, though Q2 2026 earnings beat expectations. Analyst sentiment remains positive with a consensus price target of $82.67, driven by robust CASGEVY sales growth and pipeline advancements.

Outlook: CRSP offers significant upside potential from gene-editing therapeutics, but high cash burn and negative profitability pose risks. Investment appeal hinges on successful clinical trials and market expansion of approved therapies, balanced against financial sustainability concerns in a competitive biotech landscape.

Cognizant Technology Solutions Corp

CTSH trades at $58.31, up 1.11% today, near its consensus price target of $59.92. The stock shows bullish technical signals with moving averages supporting an uptrend, though oscillators indicate overbought conditions. Recent Q2 2026 earnings missed estimates, but revenue beat expectations, and the company maintains strong profitability with a net margin of 10.26%. AI initiatives and financial services growth are key drivers, as highlighted in recent earnings calls (Seeking Alpha, 2026-07-29).

Outlook: CTSH offers value with a P/E of 12.58 and stable cash flows, but faces risks from client spending caution and competitive pressures. Upside potential exists if AI investments yield growth, though macroeconomic headwinds could limit near-term gains. Analysts are mixed, with 43% recommending buy.

Returns comparison

Trailing returns across standard periods

About Crispr Therapeutics AG

CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.

Read more on CRSP

About Cognizant Technology Solutions Corp

Cognizant is a global IT services provider, offering consulting and outsourcing services to some of the world's largest enterprises spanning the financial services, media and communications, healthcare, natural resources, and consumer products industries. Cognizant employs nearly 300,000 people globally, roughly 70% of whom are in India, although the company's headquarters are in Teaneck, New Jersey.

Read more on CTSH